Symptomatic treatment of gastroesophageal reflux disease (GERD).
Erosive reflux esophagitis.
Nonsteroidal anti-inflammatory drug (NSAID)-induced gastric and duodenal ulcers and upper gastrointestinal symptoms.
Prevention of gastric and duodenal ulcers associated with low dose aspirin (75-325 mg) therapy.
Helicobacter pylori (H. pylori) associated peptic and duodenal ulcers.
Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and idiopathic hypersecretion).
Maintenance of hemostasis and prevention of rebleeding of gastric and duodenal ulcers following treatment with esomeprazole intravenous (IV).
Other Services
Country
Account